Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Managing Side Effects with South Asian Foods July 19, 2022 EMA Recommends Granting a Marketing Authorisation for Elinzanetant September 26, 2025 Virtual Reality Found to Benefit Cancer Patients’ Mental Health October 15, 2021 Woman, 88, Had Been Waving from Her Window for Over a... May 13, 2019 Load more HOT NEWS How Therapy Helped Me Cope During Cancer: A Survivor’s Perspective Antitumour Activity of Combination of Lenvatinib and Pembrolizumab in Patients with... 10 Ways to Keep Your Family Safe from the Coronavirus Outbreak New drug combo for advanced breast cancer approved for NHS in...
